Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 188 people, all of whom received a combination of two drugs — bempegaldesleukin (also called NKTR-214) and nivolumab. Of those, 172 completed the study and 16 did not. The trial was primarily looking at what is called the "objective response rate" (ORR) — that is, the proportion of participants whose tumours showed a meaningful reduction in size, either disappearing completely or shrinking by at least 30% — specifically in people whose tumours had low levels of a protein called PD-L1 (a marker sometimes used to guide cancer treatment decisions). The reported data shows that, among participants with low PD-L1 levels, 22 people had a recorded response to the treatment combination, as assessed by an independent review panel. When looking at all 188 treated participants together, 37 people had a recorded response according to the same independent review, or 36 people when assessed by the treating doctors directly. In the low PD-L1 group, the doctors' assessment recorded 20 people with a response. The reported data also includes a measure called "duration of response" — meaning how long a response lasted in those who had one. For all treated participants, this was reported as 13.4 months by the independent review panel and 15.9 months by the treating doctors. For the low PD-L1 group specifically, the figures were 13.4 months (independent review) and 14.3 months (treating doctors). These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Bladder Cancer Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing to give written consent to take part and follow the study's procedures
- Your general health and ability to carry out daily activities meets a certain level (your doctor can assess this)
- Your cancer can be measured on scans according to standard guidelines
- You have been diagnosed with bladder or urinary tract cancer (urothelial/transitional cell carcinoma) that cannot be removed by surgery, has spread locally, or has spread to other parts of the body
- You can provide either a recent tissue sample (biopsy) or stored tissue from a previous biopsy
- You have not previously received chemotherapy or experimental treatments for your advanced or spread cancer
- You are not able to receive a chemotherapy drug called cisplatin
Who may not be able to join:
- You have an active autoimmune disease, or one that is known or suspected (a condition where the immune system attacks the body)
- You have previously been treated with a therapy called IL-2
- You have previously received certain immunotherapy drugs that target the immune system, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 treatments, or other similar immune-based therapies
- You have high blood pressure that has not been controlled on a stable treatment plan for at least 14 days before starting the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Director, Nektar Therapeutics
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Per Blinded Independent Central Review (BICR) in Patients Whose Tumors Have Low Programmed Cell Death Ligand (PD-L1) Expression
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.